 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 1 | 6 | | 1997 | 4 | 4 | 8 | | 1998 | 10 | 4 | 14 | | 1999 | 12 | 5 | 17 | | 2000 | 8 | 5 | 13 | | 2001 | 5 | 7 | 12 | | 2002 | 19 | 7 | 26 | | 2003 | 17 | 10 | 27 | | 2004 | 19 | 10 | 29 | | 2005 | 22 | 10 | 32 | | 2006 | 32 | 8 | 40 | | 2007 | 48 | 13 | 61 | | 2008 | 40 | 17 | 57 | | 2009 | 39 | 25 | 64 | | 2010 | 44 | 17 | 61 | | 2011 | 49 | 18 | 67 | | 2012 | 46 | 28 | 74 | | 2013 | 56 | 28 | 84 | | 2014 | 56 | 23 | 79 | | 2015 | 62 | 28 | 90 | | 2016 | 73 | 42 | 115 | | 2017 | 62 | 30 | 92 | | 2018 | 65 | 22 | 87 | | 2019 | 48 | 20 | 68 | | 2020 | 45 | 10 | 55 | | 2021 | 37 | 3 | 40 | | 2022 | 30 | 4 | 34 | | 2023 | 34 | 1 | 35 | | 2024 | 23 | 26 | 49 | | 2025 | 43 | 7 | 50 | | 2026 | 12 | 0 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug; 6(8):1647-1666.
-
Padilla MS, Li JJ, Zhang Q, Patwari K, Shi S, Yamagata HM, Joseph RA, Hymms BN, Teerdhala SV, Fitzgerald E, Chalom OZ, Gupta K, Alameh MG, Weissman D, Le AD, Mitchell MJ. Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Adv Mater. 2026 Aug; 38(47):e73721.
-
Barac A, Guha A, Fleming TR, Bonaca M, Thavendiranathan P, Deswal A, Amiri-Kordestani L, Bhatnagar V, Cordoba R, Hurvitz S, Adjei AA, Agarwal N. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026 Aug 04; 154(5):e188-e205.
-
Barac A, Guha A, Fleming TR, Bonaca M, Thavendiranathan P, Deswal A, Amiri-Kordestani L, Bhatnagar V, Cordoba R, Hurvitz S, Adjei AA, Agarwal N. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
-
Zhou C, Greillier L, Liu G, John T, Xing L, Kowalski D, Memmott RM, Yazici O, Sun M, Shu CA, Pons-Tostivint E, Fan Y, Fernandez-Hinojal G, Shum E, Wang M, Bertolini F, Camidge DR, Zhou C, Doucet L, Hong Q, Fang J, Huang D, Jin B, Yu Y, Antonuzzo L, Moro-Sibilot D, Bennouna J, de Castro G, Zheng L, Heymach JV. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. N Engl J Med. 2026 Aug 20; 395(8):765-775.
-
Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat Rev Drug Discov. 2026 Jul; 25(7):516-533.
-
Hargis P, Baker H, Wiesen B, Kukreja J. Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management. Urol Clin North Am. 2026 Aug; 53(3):509-516.
-
Andrade-Bucknor S, Rodriguez BPR, Ma C, Lyubarova R, Kondapalli L. Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies. Curr Cardiol Rep. 2026 Apr 23; 28(1).
-
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. J Clin Oncol. 2026 May; 44(13):1190-1197.
-
Kessler ER, Hoover K, Coats H, Fischer SM. Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer. Support Care Cancer. 2026 Mar 25; 34(4).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|